Rhabdomyosarcoma
Conditions
Interventions
experimental group:chemotherapy, radiotherapy and surgery
Sponsors
Eye Ear Nose and Throat Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
16 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 16 years old, < 70 years old; 2. ECOG performance status of 0-1; 3. Patients have a histologically confirmed diagnosis of head and neck rhabdomyosarcoma and no prior exposure to chemotherapy or radiotherapy; 4. Patients with risk divided into the IRSG middle-risk group; 5. No obvious heart, liver, kidney dysfunction and blood system diseases; 6. Prohibit the use of other drugs for the treatment of neutropenia or drugs that affect hemogram, such as Medroxyprogesterone, megestrol, adrenocortical hormone, etc.; 7. The patient and his family members signed the chemotherapy consent form and informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with poor compliance or refusal to use treatment; 2. Those with concomitant diseases that seriously impair patient safety or affect patients' inability to complete clinical trials; 3. Patients with intolerable and/or serious or life-threatening adverse events during application; 4. Women during lactation or pregnancy (urine ß-HCG positive); 5. Those who have a history of drug abuse; 6. Patients with active mental disorders or other cognitive disorders that affect the ability to sign informed consent and comprehension; 7. Other conditions that the researcher judges are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival ; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;objective remission rate; | — |
Countries
China
Contacts
Public ContactShu Tian
Eye Ear Nose and Throat Hospital, Fudan University
Outcome results
None listed